equence variations within splice sites may pose problems in the interpretation of their pathogenic effect, especially when these variations occur outside the highly conserved /gt (donor or 59 site) and ag/ (acceptor or 39 site) consensus dinucleotides that immediately flank most exons. A commonly used method to evaluate the probable effect of a sequence variation on splicing is to calculate the ShapiroSenapathy (SS) score, which is based on the extended splice site consensus sequence.
S
equence variations within splice sites may pose problems in the interpretation of their pathogenic effect, especially when these variations occur outside the highly conserved /gt (donor or 59 site) and ag/ (acceptor or 39 site) consensus dinucleotides that immediately flank most exons. A commonly used method to evaluate the probable effect of a sequence variation on splicing is to calculate the ShapiroSenapathy (SS) score, which is based on the extended splice site consensus sequence. [1] [2] [3] Here we present a sequence variation in a 59 splice site of the gene encoding fibroblast growth factor receptor type 2 (FGFR2) that maintains a consensus nucleotide at the variant position, but nevertheless causes a switch to the use of a cryptic 59 splice site within the upstream (IIIc) exon. This variant is present in three generations of a family and manifests with mild features of Crouzon syndrome.
PATIENTS AND METHODS
Following informed consent blood samples were collected from members of the family pedigree shown in fig 1. DNA was isolated by proteinase K treatment and phenol chloroform extraction. RNA was also extracted from the blood of affected individual II-2 and cDNA synthesised by standard techniques.
Mutation screening of exons IIIa and IIIc of FGFR2 4 was undertaken in DNA from the proband using WAVE (3500HT; Transgenomic) denaturing high performance liquid chromatography. 5 Sequencing was performed with Big Dye (version 3) on an ABI 3100 DNA sequencer.
Oligonucleotide hybridisation was carried out on cDNA derived from individual II-2. Reverse transcriptase PCR (RT-PCR) using primers 4F and 9R located respectively in FGFR2 exons 6 and 12 (exon numbering according to Kan et al 5 ; see  fig 2A) , was performed as previously described. 7 The RT-PCR product was separated by electrophoresis on a 2% agarose gel, blotted onto a nylon membrane (Zeta-Probe, Bio-Rad), and the presence of various potential splicing products was analysed by hybridisation to specific 32 P radiolabelled oligonucleotide probes 7 SPL7/8 (IIIa-IIIb), SPL7/9 (IIIa-IIIc) and SPL7/11 (IIIa-exon 12). An additional probe 9C/TM (59-TGCTTGGCGGCGCCTGGAA-39) was used to detect splicing of the cryptic donor splice site in exon IIIc to the downstream transmembrane exon 11.
RESULTS AND DISCUSSION
The family pedigree is shown in fig 1A and the facial phenotype is illustrated in fig 1B. The proband III-3 presented aged 3K years with scaphocephaly and exorbitism. He was found to have sagittal and partial metopic synostosis, which was corrected surgically. His mother II-2, uncle II-3 ( fig 1B) and grandfather I-1 (not illustrated) had a similar facial appearance but had not undergone any reconstructive surgery.
In view of the features of mild Crouzon syndrome we screened exons IIIa and IIIc of FGFR2. This revealed heterozygosity for a nucleotide transition, 1084+3ARG, located at the third (intronic) base of the 59 splice site lying downstream of the alternatively spliced exon IIIc. The mutation was independently confirmed by demonstrating a new cleavage site for the restriction enzyme AccI (not shown). The same substitution was identified by DNA sequencing in three other clinically affected family members, I-1, II-2, and II-3, but not in two clinically unaffected individuals at 50% prior risk (II-4 and II-5). Although this nucleotide change has been described twice before, in a child with Pfeiffer syndrome whose parents were normal on DNA testing, 10 and in a clinically unclassified patient with sagittal and lambdoid synostosis, 11 these reports did not include verification of sample relationships, nor experimental data documenting the pathogenic mechanism of the mutation. We therefore sought to obtain direct evidence of an effect of this putative mutation on splicing.
The results of the oligonucleotide hybridisations are shown in figs 2B-E. Whereas the normal control sample only showed the expected exon IIIc splice product ( fig 2B, lane  N) , two additional shorter products were identifiable in the patient sample. DNA sequencing and hybridisation to specific oligonucleotides showed that one of these arose from direct splicing of exon IIIa to exon 12 ( fig 2E) , whereas the other utilised a cryptic splice site within exon IIIc (59-CGGgtaatt-39; new intronic nucleotides in lower case) (figs 2B, C). This cryptic splice site was previously known, both because it is N Our data elucidate the mechanism of the 1084+3ARG mutation and confirm its pathogenicity.
activated by the pathogenic synonymous substitution 1032GRA in exon IIIc (Ala344Ala mutation), 4 creating the donor splice site 59-CAGgtaatt-39 12 13 and because the wildtype cryptic sequence is utilised in a mutant allele with a 6 nucleotide insertion that destroys the normal 59 splice site. 14 There was no evidence for ectopic expression of the alternatively spliced IIIb exon ( fig 2D) . 7 The activation of the cryptic splice site by the 1084+3ARG initially seemed surprising, because the consensus at +3 is either A or G, with A being slightly more prevalent than G in a large survey of 59 splice sites. 1 2 However the SS score of splice site strength is somewhat lower for the mutated than the authentic splice site (75.39 wild-type against 72.25 mutated), and the difference is accentuated by several other methods used to calculate splice site strength (table 1) . Interestingly, by two of these methods (SS and DG), the cryptic IIIc splice site is actually stronger than the authentic one. This suggests that only a mild reduction in strength of the wild-type site, as occurs in the case of the 1084+3ARG mutation, is sufficient to tip the balance towards use of the cryptic splice site. This analysis also shows that the cryptic site is further strengthened by the synonymous 1032GRA mutation (table 1).
In the complex process of splice site recognition, the RNA sequence in U1 small nuclear ribonucleoprotein plays an important role by binding to the 59 splice site at the 22 to +6 positions. 18 The effect of the 1084+3ARG mutation is to reduce complementarity of the authentic 59 site to the U1 sequence, whereas the 1032GRA mutation enhances complementarity of the cryptic site (see DG values in table 1). The consequence of both mutations is similar: the preferential synthesis of FGFR2 mRNA lacking 51 nucleotides in the IIIc exon, thus encoding a protein that lacks 17 amino acids. It has previously been noted that the 1032GRA mutation is associated with a milder phenotype than most FGFR2 mutations 19 and, based on the clinical phenotype of the present family, this also appears to be the case for 1084+3ARG.
Ohno et al 20 proposed that +3ARG mutations at 59 splice sites are pathogenic when both the +4, and one or other of the +5/+6 positions, are not complementary to U1 in the wildtype sequence; the authentic FGFR2 IIIc 59 splice site indeed obeys this rule (+4 and +5 are non-complementary; table 1). In summary, our data elucidate the mechanism of the 1084+3ARG mutation and confirm its pathogenicity. Although a G at +3 is frequently recognised as part of the 59 splice consensus, in a small number of documented cases +3A is nevertheless essential to accomplish normal splicing. 6 (B-E) Blot hybridisation analysis of RT-PCR products using primers 4F (exon 6) and 9R (exon 12). The originating RNA was extracted from whole blood from II-2 (heterozygous for the 1084+3ARG mutation) (P), whole blood from a normal control (N), and control keratinocytes (K). (B) Oligonucleotide SPL7/9 matches the IIIa-IIIc boundary and normally detects a 640 bp product. In the patient, an additional smaller product is detected. (C) This product (589 bp) specifically hybridises to the 9C/TM oligonucleotide, showing that it is generated by use of the cryptic 59 splice site within exon IIIc. The larger fragments are heteroduplexes. (D) An oligonucleotide (SPL7/8) diagnostic for the 643 bp IIIb splice form does not hybridise to the patient lane, but is positive in a keratinocyte sample that characteristically expresses this alternative splice form. (E) The patient sample also expresses lower amounts of a smaller 292 bp product that is identified using SPL7/10 as a IIIa-exon 12 splice form. This product was not present in control cDNA, but has been observed previously 7 8 and might have a physiological function. 9 Size markers are HaeIII-digested QX174 DNA. 
